Company news
Unicycive Therapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
July 16, 2024
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
July 10, 2024
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)
July 9, 2024
Unicycive Therapeutics Joins Russell Microcap® Index
June 30, 2024
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
June 24, 2024
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress
May 27, 2024
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference
May 22, 2024
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
May 14, 2024
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
May 12, 2024
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
April 9, 2024
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
March 27, 2024
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
March 24, 2024
Unicycive Announces $50 Million Private Placement
March 13, 2024
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
March 12, 2024
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
March 6, 2024
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
March 3, 2024
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
February 13, 2024
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
January 28, 2024
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
January 22, 2024
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
December 17, 2023
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
November 28, 2023
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
October 22, 2023
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
September 5, 2023
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
August 28, 2023
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
August 13, 2023
Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
July 19, 2023
Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
July 17, 2023
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
June 28, 2023
Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9: 00 A.M. ET
June 15, 2023
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
April 23, 2023
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
March 30, 2023
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
March 5, 2023
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
February 26, 2023
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
February 1, 2023
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
January 22, 2023
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
January 4, 2023
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
December 28, 2022
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
December 27, 2022
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
December 21, 2022
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
November 20, 2022
Unicycive Announces Third Quarter Financial Results and Provides Business Update
November 13, 2022
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
November 9, 2022
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)
September 6, 2022
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
August 23, 2022
Unicycive Announces Second Quarter Financial Results and Provides Business Update
August 14, 2022
Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets
July 17, 2022
Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia
June 1, 2022
Decks
- Investor Presentation (October 2026)
Investor deck · 33 slides · October 2026
- Technical Presentation (June 2024)
Technical · 29 slides · Jun 25, 2024
- Corporate Update (December 2022)
Corporate update · 12 slides · Dec 28, 2022